
    
      IBI101 and Sintilimab will be administered intravenously on Day 1 of every 21 days. The DLT
      observation period is 21 days starting with the first dose taken on day 1. In Phase Ia study,
      eight dose levels of IBI101 (0.01, 0.1, 0.3, 1, 3, 6, 10 and 15mg/kg) will be tested. In
      Phase Ib study, four dose levels of IBI101 (1, 3, 6 and 10mg/kg) in combination with
      Sintilimab 200mg will be tested. After dose escalation phase completed, two combination dose
      cohorts (IBI101 3mg/kg and 6mg/kg in combination with Sintilimab 200mg) will be expanded to
      10 patients each.

      IBI101 is a recombinant fully humanized IgG1 anti-tumor necrosis factor receptor superfamily
      member 4 (OX40) monoclonal antibody.

      Sintilimab is a recombinant fully humanized anti-programmed death 1 (PD1) monoclonal
      antibody.
    
  